If you’re on the hunt for stocks to watch today, Seelos Therapeutics, Inc. (NASDAQ:SEEL) is a stock to give close attention to. The company shares are trading 0.63% or 0.01 points up from last closing price of $1.6, reaching $1.61 at last check. The SEEL share price has risen in 3 of the last 5 days and is down -37.69% over the past week. It will be exciting to see whether the stock manages to continue increasing or take a minor break for the next few days. The move came on weak volume too with far less shares changing hands than in a normal session. Trading activity as of this writing weakened by -123,948 shares, and in total 72152 shares valued at $116165 were seen changing hands compared with 196100 shares valued at $313760 recorded at the previous session. You should take into consideration that a falling volume on higher prices causes divergence and may be an early warning about possible changes in SEEL stock for the next couple of days.
Seelos Therapeutics, Inc. (SEEL) shares have notched a 3-month decline of about -37.69%, but has still tumbled -71.01% year to date. By comparison, the stock sank -80.14% over the past 12 months, while it slipped -20.85% over the 1 month. The company’s market cap is around $35.47M, with its short interest ratio standing at 1.83%.
In the current trading session for SEEL, the stock witnessed two major price actions, it rose to a high of $1.67 and was down as much as $1.5848 at one point. The high recorded is very low when compared to their 52-week high which is $1.32. The 52-week high is now at -87.36 distance from current price. Their recent low of $12.82 represents a 22.73% recovery. This data is quite important for investors who look to benefit from the recent rise of the company’s stock. The price target currently for SEEL is $6, this is below the recent high that the stock attained. Taking a look at the overall sentimental views of financial analysts, the trading pattern of this stock recently is very clear.
SEEL‘s last price was down -63.26% as compared to the average trading price of 50 days recorded at $4.38 while enlarging the period to 200 trading days, the average closing price was $2.02. At present, there are 21.24 million in the total number of common shares owned by the public and among those 17.42 million shares have been available to trade. The percentage of shares being held by the company management was 18.48% while institutions stake was 12%. The company has generated negative returns on equity over the last 12 months (0%). It managed to keep its gross profit margin at 0% over the past 12 months.
When assessing the full upside of the SEEL stock, there is another set of technicals that should be looked into and considered. Its -5.94% decline from moving average of $1.71 has brought about a negative sentiment when calculated over the last 20 days. The market has allocated a beta of 0.75 to the stock. With the beta been less than one, this implies that the company shares are theoretically less volatile than the market, something that the traders definitely are keeping an eye on.
Most of the analysts surveyed by Thomson/First Call think quite highly of Seelos Therapeutics, Inc. — 2 analysts rate the stock as a buy with another 0 rating it strong buy. There are 0 analysts who maintain a hold rating for the stock, with 0 giving it a sell rating. Analysts arrived at a 12-month price target of $6 on shares of Seelos Therapeutics, Inc. (NASDAQ:SEEL), which corresponds to 267.40% upside potential than its current market price of $1.61 and implies potential despite the recent advance in the price. However, their current target price has fallen from $6 a month ago and is down handily from the consensus target of $6 a quarter ago.
In the last five years, the EPS of the company has been roughly 38.6%. Though the percentage looks encouraging, extra headwinds are emerging as looking out over a next 5-year period, with analysts estimating that their earnings will decrease annually by 0%. The revenue of the company has retreated at an average annualized rate of about 0 over the last five years. The company recently recorded a drop of 0%, but this figure is rather unattractive.
Let’s briefly check the hedge fund interest towards SEEL stock. Vanguard Group Inc. added position in the company after it grew 104.2% or 117,151 shares of its common stock. The hedge fund now owns 239,222 shares worth $385,147, SEC documents show. A.R.T. Advisors LLC shored up assets in the stock as 11101.17 shares have been purchased, increasing its stake by 371.5% to 52,342 shares which are currently valued at $84,271. In addition, BlackRock Inc. recently reported that it now owns 311,528 shares making a total of $501,560 based on the recent price. This refelects a change of 15.3% in their ownership.